Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction (Q38253151)

1 September 2017

Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction (English)

1 reference

1 September 2017

Hagai Tavori

1

1 reference

PubMed ID

25244623

1 September 2017

Michelle Melone

series ordinal

2

1 reference

PubMed ID

25244623

1 September 2017

Shirya Rashid

series ordinal

3

1 reference

1 September 2017

1 October 2014

1 reference

Expert Review of Cardiovascular Therapy

1 September 2017

1 reference

1 September 2017

12

1 reference

1 September 2017

10

1 reference

1 September 2017

1137-1144

1 reference

Mechanisms of disease: genetic causes of familial hypercholesterolemia

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

SREBPs: transcriptional mediators of lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Managing the underestimated risk of statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

An assessment by the Statin Liver Safety Task Force: 2014 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Statin treatment and new-onset diabetes: a review of proposed mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Structure of a serine protease proteinase K from Tritirachium album limber at 0.98 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Structural comparison of two serine proteinase-protein inhibitor complexes: eglin-c-subtilisin Carlsberg and CI-2-subtilisin Novo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The crystal structure of the proprotein processing proteinase furin explains its stringent specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Molecular basis for LDL receptor recognition by PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The biology and therapeutic targeting of the proprotein convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Plasma PCSK9 preferentially reduces liver LDL receptors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Genetic and metabolic determinants of plasma PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Self-association of human PCSK9 correlates with its LDLR-degrading activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Isolation and characterization of the circulating truncated form of PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The safety and side effects of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

PCSK9: a convertase that coordinates LDL catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Development trends for human monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Adiponectin, cardiovascular function, and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Novel drug approaches in development for the treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Phase 3 data for PCSK9 inhibitor wows.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Clinically useful monoclonal antibodies in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Executive Summary: Heart Disease and Stroke Statistics—2014 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Plasma PCSK9 levels correlate with cholesterol in men but not in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

Structure of Subtilisin BPN′ at 2.5 Å Resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2014.954551

10.1586/14779072.2014.954551

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25244623